The Next Generation of Antivirals

Thylacine Bio is developing the Peptide Platform for Infectious Disease

our Approach

Treat illness, prevent infection, block transmission

Our therapeutics are designed to combat persistent endemic respiratory viruses of concern and help prepare for future outbreaks by treating disease, preventing infection, and blocking transmission.

Broad spectrum

Pipeline candidates include commercial and biothreat therapeutics that protect against multiple pathogens within a family of viruses.

A resilient, scalable approach against emerging viruses.

Our platform can be rapidly tuned and applied to new and existing pathogens. We target conserved regions that are less susceptible to mutation, unlocking efficacy across variants. The resulting antivirals are potent, self-administered, and easily distributed.

meet the team
In the News